AstraZeneca on Sept. 8 shut down its clinical trial evaluating a potential vaccine for COVID-19, but CEO Pascal Soriot said the vaccine could still be available by the end of the year, Business Insider reports.
The biopharmaceutical company paused the global clinical trial after a participant in the United Kingdom suffered an adverse reaction.
The New York Times reported the illness as transverse myelitis, an inflammation of the spinal cord that interrupts messages that nerves send throughout the body.
AstraZeneca has initiated a safety review and has not given a timeline for when the trial may resume.